{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.51","upperLimit":"90.15","value":"85.00"},{"groupId":"OG001","lowerLimit":"78.21","upperLimit":"93.84","value":"87.50"},{"groupId":"OG002","lowerLimit":"72.38","upperLimit":"90.09","value":"82.50"}]}],"title":"SC Preference"},{"categories":[{"measurements":[{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"13.8"},{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"12.5"},{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"15.0"}]}],"title":"IV Preference"},{"categories":[{"measurements":[{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.3"},{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.0"},{"comment":"As per the statistical analysis plan, a 95% confidence interval was only calculated for the percentage of participants who preferred PH FDC SC.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"2.5"}]}],"title":"No Preference"}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Question 1 of the Patient Preference Questionnaire (PPQ) asked participants the following question: \"All things considered, which method of administration did you prefer?\" The three available options for a participant's response were: IV, SC, or No preference. A point estimate with associated exact Clopper-Pearson binomial 95% confidence interval was calculated only for the percentage of participants who preferred PH FDC SC.","dispersionType":"95% Confidence Interval","groups":[{"description":"In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Participants"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-Treat (mITT) Population: All randomized participants, allocated to their randomized treatment arm, who received at least one dose by both SC and IV routes of administration during the Treatment Cross-over Period and subsequently answered at least Question 1 of the PPQ.","reportingStatus":"POSTED","timeFrame":"Cycle 6 Day 1 (each cycle is 21 days)","title":"Percentage of Participants by Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 1 of the Patient Preference Questionnaire (PPQ)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}